中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (5): 402-409.doi: 10.35541/cjd.20220909
《蕈样肉芽肿治疗中国专家共识（2023）》编写专家组
收稿日期:2022-12-21
修回日期:2023-03-09
发布日期:2023-05-04
通讯作者:
沈小雁；郑捷
E-mail:shenxiaoyan2018@139.com; jie-zheng2001@126.com
Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （2023）”
Received:2022-12-21
Revised:2023-03-09
Published:2023-05-04
Contact:
Shen Xiaoyan; Zheng Jie
E-mail:shenxiaoyan2018@139.com; jie-zheng2001@126.com
摘要： 【摘要】 蕈样肉芽肿（MF）是皮肤T细胞淋巴瘤最常见类型，早期仅累及皮肤，进展期出现肿块并有淋巴结、外周血和内脏受累。治疗前需对患者进行分期评估，根据分期选择治疗方案。我国12位MF诊疗领域专家在国外最新指南和共识的基础上，回顾了治疗方法的循证医学级别，结合我国现状，在MF一线、二线治疗方案和新疗法等方面达成共识，为规范MF治疗提供指导。
《蕈样肉芽肿治疗中国专家共识》编写专家组. [开放获取] 蕈样肉芽肿治疗中国专家共识（2023）[J]. 中华皮肤科杂志, 2023,56(5):402-409. doi:10.35541/cjd.20220909
Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023）[J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.doi:10.35541/cjd.20220909
| ［1］ | Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO⁃EORTC classification for primary cutaneous lymphomas. Blood. 2019;133（16）:1703⁃1714［J］. Blood, 2019,134（13）:1112. doi: 10.1182/blood.2019002852. |
| ［2］ | Kaufman AE, Patel K, Goyal K, et al. Mycosis fungoides: developments in incidence, treatment and survival［J］. J Eur Acad Dermatol Venereol, 2020,34（10）:2288⁃2294. doi: 10.1111/ jdv.16325. |
| ［3］ | Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome ⁃ Update 2017［J］. Eur J Cancer, 2017,77:57⁃74. doi: 10.1016/j.ejca.2017. 02.027. |
| ［4］ | Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018［J］. Br J Dermatol, 2019,180（3）:496⁃526. doi: 10.1111/bjd.17240. |
| ［5］ | National Comprehensive Cancer Network. 2022 NCCN Guidelines Primary Cutaneous Lymphomas［EB/OL］. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. |
| ［6］ | Phyo ZH, Shanbhag S, Rozati S. Update on biology of cutaneous T⁃cell lymphoma［J］. Front Oncol, 2020,10:765. doi: 10.3389/fonc.2020.00765. |
| ［7］ | Krejsgaard T, Litvinov IV, Wang Y, et al. Elucidating the role of interleukin⁃17F in cutaneous T⁃cell lymphoma［J］. Blood, 2013,122（6）:943⁃950. doi: 10.1182/blood⁃2013⁃01⁃480889. |
| ［8］ | Hodak E, Geskin L, Guenova E, et al. Real⁃life barriers to diagnosis of early mycosis fungoides: an international expert panel discussion［J］. Am J Clin Dermatol, 2023,24（1）:5⁃14. doi: 10.1007/s40257⁃022⁃00732⁃w. |
| ［9］ | Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides［J］. J Am Acad Dermatol, 2005,53（6）:1053⁃1063. doi: 10.1016/j.jaad.2005.08.057. |
| ［10］ | Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas （ISCL） and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer （EORTC）［J］. Blood, 2007,110（6）:1713⁃1722. doi: 10.1182/blood⁃2007⁃03⁃055749. |
| ［11］ | Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer［J］. J Clin Oncol, 2011,29（18）:2598⁃2607. doi: 10.1200/JCO. 2010.32.0630. |
| ［12］ | Larocca C, Kupper T. Mycosis fungoides and Sézary syndrome: an update［J］. Hematol Oncol Clin North Am, 2019,33（1）:103⁃120. doi: 10.1016/j.hoc.2018.09.001. |
| ［13］ | Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model［J］. J Clin Oncol, 2015,33（32）:3766⁃3773. doi: 10.1200/JCO.2015.61.7142. |
| ［14］ | OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence［EB/OL］. http://www.cebm.net/index.aspx?oZ5653. |
| ［15］ | Zackheim HS, Kashani⁃Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients［J］. Arch Dermatol, 1998,134（8）:949⁃954. doi: 10.1001/archderm.134.8. 949. |
| ［16］ | Kartan S, Shalabi D, O′Donnell M, et al. Response to topical corticosteroid monotherapy in mycosis fungoides［J］. J Am Acad Dermatol, 2021,84（3）:615⁃623. doi: 10.1016/j.jaad.2020.05.043. |
| ［17］ | Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T⁃cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides［J］. JAMA Dermatol, 2013,149（1）:25⁃32. doi: 10.1001/2013.jamadermatol.541. |
| ［18］ | Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real⁃world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T⁃cell lymphoma［J］. Am J Clin Dermatol, 2021,22（3）:407⁃414. doi: 10.1007/s40257⁃021⁃00591⁃x. |
| ［19］ | Correia E, Krishnasamy S, Suriano JG, et al. Response to chlormethine/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single⁃center retrospective study［J］. Clin Lymphoma Myeloma Leuk, 2022,22（8）:581⁃588. doi: 10.1016/j.clml.2022.02.002. |
| ［20］ | Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early⁃stage cutaneous T⁃cell lymphoma: results of the phase Ⅲ clinical trial［J］. J Am Acad Dermatol, 2003,49（5）:801⁃815. doi: 10.1016/s0190⁃9622（03）01475⁃0. |
| ［21］ | Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open⁃label pilot study［J］. J Am Acad Dermatol, 2004,50（4）:600⁃607. doi: 10. 1016/j.jaad.2003.09.005. |
| ［22］ | Shipman AR, Scarisbrick J. New treatment options for mycosis fungoides［J］. Indian J Dermatol, 2016,61（1）:119. doi: 10. 4103/0019⁃5154.174085. |
| ［23］ | Gilchrest BA, Parrish JA, Tanenbaum L, et al. Oral methoxsalen photochemotherapy of mycosis fungoides［J］. Cancer, 1976,38（2）:683⁃689. doi: 10.1002/1097⁃0142（197608）38:2<683::aid⁃cncr2820380210>3.0.co;2⁃v. |
| ［24］ | Hofer A, Cerroni L, Kerl H, et al. Narrowband （311⁃nm） UV⁃B therapy for small plaque parapsoriasis and early⁃stage mycosis fungoides［J］. Arch Dermatol, 1999,135（11）:1377⁃1380. doi: 10.1001/archderm.135.11.1377. |
| ［25］ | Phan K, Ramachandran V, Fassihi H, et al. Comparison of narrowband UV⁃B with psoralen⁃UV⁃A phototherapy for patients with early⁃stage mycosis fungoides: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（3）:335⁃341. doi: 10.1001/jamadermatol.2018.5204. |
| ［26］ | Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium［J］. J Am Acad Dermatol, 2016,74（1）:27⁃58. doi: 10.1016/j.jaad.2015.09.033. |
| ［27］ | Pavlotsky F, Hodak E, Ben Amitay D, et al. Role of bath psoralen plus ultraviolet A in early⁃stage mycosis fungoides［J］. J Am Acad Dermatol, 2014,71（3）:536⁃541. doi: 10.1016/j.jaad. 2014.04.011. |
| ［28］ | Trovato E, Pellegrino M, Filippi F, et al. Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1［J］. G Ital Dermatol Venereol, 2020,155（3）:306⁃311. doi: 10.23736/S0392⁃0488.18.05867⁃4. |
| ［29］ | Deaver D, Cauthen A, Cohen G, et al. Excimer laser in the treatment of mycosis fungoides［J］. J Am Acad Dermatol, 2014,70（6）:1058⁃1060. doi: 10.1016/j.jaad.2014.01.915. |
| ［30］ | Xue J, Liu C, Liu Y. Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: a systemic review［J］. Photodiagnosis Photodyn Ther, 2017,17:87⁃91. doi: 10.1016/j.pdpdt.2016.11.010. |
| ［31］ | Vieyra⁃Garcia P, Fink⁃Puches R, Porkert S, et al. Evaluation of low⁃dose, low⁃frequency oral psoralen⁃UV⁃A treatment with or without maintenance on early⁃stage mycosis fungoides: a randomized clinical trial［J］. JAMA Dermatol, 2019,155（5）:538⁃547. doi: 10.1001/jamadermatol.2018.5905. |
| ［32］ | Moraes FY, Carvalho Hde A, Hanna SA, et al. Literature review of clinical results of total skin electron irradiation （TSEBT） of mycosis fungoides in adults［J］. Rep Pract Oncol Radiother, 2014,19（2）:92⁃98. doi: 10.1016/j.rpor.2013.08.003. |
| ［33］ | Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer （EORTC） Cutaneous Lymphoma Project Group［J］. J Am Acad Dermatol, 2002,47（3）:364⁃370. doi: 10.1067/mjd.2002. 123482. |
| ［34］ | Song A, Gochoco A, Zhan T, et al. A prospective cohort study of condensed low⁃dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life［J］. J Am Acad Dermatol, 2020,83（1）:78⁃85. doi: 10.1016/j.jaad.2020.01.046. |
| ［35］ | Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group［J］. Int J Radiat Oncol Biol Phys, 2015,92（1）:32⁃39. doi: 10.1016/j.ijrobp. 2015.01.008. |
| ［36］ | Zhang C, Duvic M. Treatment of cutaneous T⁃cell lymphoma with retinoids［J］. Dermatol Ther, 2006,19（5）:264⁃271. doi: 10. 1111/j.1529⁃8019.2006.00083.x. |
| ［37］ | Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene （Targretin capsules） for the treatment of refractory or persistent early⁃stage cutaneous T⁃cell lymphoma［J］. Arch Dermatol, 2001,137（5）:581⁃593. doi: 10⁃1001/pubs.Arch Dermatol.⁃ISSN⁃0003⁃987x⁃137⁃5⁃dst0039. |
| ［38］ | Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced⁃stage cutaneous T⁃cell lymphoma: multinational phase Ⅱ -Ⅲ trial results［J］. J Clin Oncol, 2001,19（9）:2456⁃2471. doi: 10.1200/JCO.2001.19.9.2456. |
| ［39］ | Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen⁃ultraviolet A （PUVA） compared with PUVA treatment alone in stage IB⁃IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase Ⅲ randomized clinical trial （NCT00056056）［J］. Br J Dermatol, 2012,167（3）:678⁃687. doi: 10.1111/j.1365⁃2133.2012.11156.x. |
| ［40］ | Ginsburg E, Hennessy K, Mhaskar R, et al. Treatment of early⁃stage mycosis fungoides with oral bexarotene and phototherapy: a systematic review and meta⁃analysis［J］. Dermatol Ther, 2022,35（5）:e15418. doi: 10.1111/dth.15418. |
| ［41］ | Bunn PA Jr, Foon KA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T⁃cell lymphomas［J］. Ann Intern Med, 1984,101（4）:484⁃487. doi: 10.7326/0003⁃4819⁃101⁃4⁃484. |
| ［42］ | Spaccarelli N, Rook AH. The Use of Interferons in the treatment of cutaneous T⁃cell lymphoma［J］. Dermatol Clin, 2015,33（4）:731⁃745. doi: 10.1016/j.det.2015.05.008. |
| ［43］ | Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon ⁃2a plus acitretin versus interferon ⁃2a plus PUVA in patients with cutaneous T⁃cell lymphoma stages Ⅰ and Ⅱ［J］. Blood, 1998,92（10）:3578⁃3581. doi: 10.1182/blood.V92.10.3578. |
| ［44］ | Aviles A, Neri N, Fernandez⁃Diez J, et al. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T⁃cell lymphoma［J］. Hematology, 2015,20（9）:538⁃542. doi: 10.1179/1607845415Y. 0000000002. |
| ［45］ | Alenezi F, Girard C, Bessis D, et al. Benefit/risk ratio of low⁃dose methotrexate in cutaneous lesions of mycosis fungoides and Sézary syndrome［J］. Acta Derm Venereol, 2021,101（2）:adv00384. doi: 10.2340/00015555⁃3719. |
| ［46］ | Tirelli U, Errante D, van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate⁃grade and high⁃grade non⁃Hodgkin′s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol, 1998,16（1）:27⁃34. doi: 10.1200/JCO.1998.16.1.27. |
| ［47］ | Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase Ⅱ trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012［J］. J Clin Oncol, 2012,30（33）:4091⁃4097. doi: 10.1200/JCO.2011.39.8065. |
| ［48］ | Knobler R, Arenberger P, Arun A, et al. European dermatology forum ⁃ updated guidelines on the use of extracorporeal photopheresis 2020 ⁃ part 1［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:2693⁃2716. doi: 10.1111/jdv.16890. |
| ［49］ | Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors［J］. Nat Rev Drug Discov, 2006,5（9）:769⁃784. doi: 10.1038/nrd2133. |
| ［50］ | Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat （suberoylanilide hydroxamic acid, SAHA） for refractory cutaneous T⁃cell lymphoma （CTCL）［J］. Blood, 2007,109（1）:31⁃39. doi: 10.1182/blood⁃2006⁃06⁃025999. |
| ［51］ | Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T⁃cell lymphoma［J］. J Clin Oncol, 2010,28（29）:4485⁃4491. doi: 10.1200/JCO.2010.28.9066. |
| ［52］ | Foss F, Advani R, Duvic M, et al. A Phase Ⅱ trial of Belinostat （PXD101） in patients with relapsed or refractory peripheral or cutaneous T⁃cell lymphoma［J］. Br J Haematol, 2015,168（6）:811⁃819. doi: 10.1111/bjh.13222. |
| ［53］ | Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real⁃world study in China［J］. J Hematol Oncol, 2017,10（1）:69. doi: 10.1186/s13045⁃017⁃0439⁃6. |
| ［54］ | Kim YH, Bagot M, Pinter⁃Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T⁃cell lymphoma （MAVORIC）: an international, open⁃label, randomised, controlled phase 3 trial［J］. Lancet Oncol, 2018,19（9）:1192⁃1204. doi: 10.1016/S1470⁃2045（18）30379⁃6. |
| ［55］ | Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician′s choice in cutaneous T⁃cell lymphoma: final data［J］. Blood Adv, 2021,5（23）:5098⁃5106. doi: 10.1182/bloodadvances.2021004710. |
| ［56］ | Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician′s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub⁃analysis［J］. Eur J Cancer, 2021,148:411⁃421. doi: 10.1016/j.ejca.2021.01.054. |
| ［57］ | Domingo⁃Domenech E, Duarte RF, Boumedil A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation［J］. Bone Marrow Transplant, 2021,56（6）:1391⁃1401. doi: 10.1038/s41409⁃020⁃01197⁃3. |
| ［58］ | Iqbal M, Reljic T, Ayala E, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta⁃analysis［J］. Biol Blood Marrow Transplant, 2020,26（1）:76⁃82. doi: 10.1016/j.bbmt.2019.08.019. |
| ［59］ | Dumont M, Peffault de Latour R, Ram⁃Wolff C, et al. Allogeneic hematopoietic stem cell transplantation in cutaneous T⁃cell lymphomas［J］. Cancers （Basel）, 2020,12（10）. doi: 10.3390/cancers12102856. |
| [1] | 李越 吴金燕 袁若月 杨屈杨 赵贤省 朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 698-702. |
| [2] | 黄晓燕 肖易 敬丹榕 陈明亮 沈敏学. 湖南省某砷尾矿地区居民砷中毒皮肤损害患病率及相关因素调查[J]. 中华皮肤科杂志, 2023, 56(7): 636-641. |
| [3] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625. |
| [4] | 宋德宇 王嘉玥 耿佳 邹美熔 李仲桃 陈玉沙 汪盛. GJB2基因p.N54H突变致经典型Vohwinkel综合征1例[J]. 中华皮肤科杂志, 2023, 56(7): 669-672. |
| [5] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495. |
| [6] | 陈奇权 杨显杰 顾恒 徐金华 郝飞 姚煦 宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539. |
| [7] | 中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488. |
| [8] | 梁云生 黎展宏 伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558. |
| [9] | 杨娜丽 许秋阳 吴含文 叶雅慧 朱吉玲 刘晶晶 李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524. |
| [10] | 陈奇权 孔敏敏 杨显杰 王欢 李健 张名望 宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503. |
| [11] | 苏畅 隋秀丽 刘瑞玲 曹毅群 姜虹 严彩蓉 王惠平 亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517. |
| [12] | 王鑫 刘丽娟 李邻峰. [开放获取] 我国慢性自发性荨麻疹临床特征：基于多家医院问卷调查的流行病学研究[J]. 中华皮肤科杂志, 2023, 56(6): 525-530. |
| [13] | 李丽俏 彭聪 陈翔 李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511. |
| [14] | 魏瑾 闫会文 赵天威 冉立伟 伦文辉 张建中. 乳头乳晕湿疹样透明细胞棘皮瘤：国内首报及文献分析[J]. 中华皮肤科杂志, 2023, 56(6): 545-548. |
| [15] | 任芬芬 王鹏 张景展 康晓静. 基于网络药理学预测中药在抗卡波西肉瘤血管生成治疗中的潜在有效成分及分子作用机制[J]. 中华皮肤科杂志, 2023, 56(5): 428-433. |
|
